An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease

AIMS: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers. METHODS: This was a randomiz...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Clin Pharmacol
Päätekijät: Süssmuth, Sigurd D, Haider, Salman, Landwehrmeyer, G Bernhard, Farmer, Ruth, Frost, Chris, Tripepi, Giovanna, Andersen, Claus A, Di Bacco, Marco, Lamanna, Claudia, Diodato, Enrica, Massai, Luisa, Diamanti, Daniela, Mori, Elisa, Magnoni, Letizia, Dreyhaupt, Jens, Schiefele, Karin, Craufurd, David, Saft, Carsten, Rudzinska, Monika, Ryglewicz, Danuta, Orth, Michael, Brzozy, Sebastian, Baran, Anna, Pollio, Giuseppe, Andre, Ralph, Tabrizi, Sarah J, Darpo, Borje, Westerberg, Goran
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BlackWell Publishing Ltd 2015
Aiheet:
Clinical Trials
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4345957/
https://ncbi.nlm.nih.gov/pubmed/25223731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12512
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia